Daygen L. Finch

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

Matti Annala, Gillian Vandekerkhove, Daniel Khalaf et al. · Cancer Discovery · 2018 · 522 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

Daniel Khalaf, Matti Annala, Sinja Taavitsainen et al. · The Lancet Oncology · 2019 · 352 citations

Medicine, Oncology, Pharmacotherapy +17

Extrapulmonary small cell cancer

Kamal Haider, Rabia Shahid, Daygen L. Finch et al. · Cancer · 2006 · 123 citations · Full text

Medicine, Oncology, Gynecologic Oncology +12

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Nicolette M. Fonseca, Corinne Maurice‐Dror, Cameron Herberts et al. · Nature Communications · 2024 · 120 citations · Full text

Medicine, Biostatistics, Oncology +17